Patents by Inventor Thomas J. Anchordoquy

Thomas J. Anchordoquy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10512687
    Abstract: The disclosed compositions and methods relate to an immunogenic composition that, in certain aspects, comprise cationic liposomes; a mixture of toll like receptor 3 (TLR3) and toll like receptor 9 (TLR9) ligands; and a cellular adhesion agent, and methods of using such compositions. In certain aspects, disclosed compositions are administered to a mammal to induce a non-specific innate immune response at mucosal surfaces. In further aspects, disclosed compositions are administered to a mammal in conjunction with an antigen to enhance the immune response of the mammal to the antigen.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: December 24, 2019
    Assignees: Colorado State University Research Foundation, The Regents of the University of Colorado, a body corporate
    Inventors: Steven Dow, Michael R. Lappin, William H. Wheat, Lyndah Chow, Daniel P. Regan, Thomas J. Anchordoquy
  • Publication number: 20180116988
    Abstract: Methods of preventing, treating or ameliorating autoimmune diabetes by modulating the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of methyldopa. Pharmaceutical compositions containing therapeutically effective amounts of methyldopa in extended release formulations and methods of using the same are also provided.
    Type: Application
    Filed: May 27, 2016
    Publication date: May 3, 2018
    Inventors: Thomas J. ANCHORDOQUY, Peter A. GOTTLIEB, Aaron MICHELS, David OSTROV
  • Publication number: 20170281754
    Abstract: The disclosed compositions and methods relate to an immunogenic composition that, in certain aspects, comprise cationic liposomes; a mixture of toll like receptor 3 (TLR3) and toll like receptor 9 (TLR9) ligands; and a cellular adhesion agent, and methods of using such compositions. In certain aspects, disclosed compositions are administered to a mammal to induce a non-specific innate immune response at mucosal surfaces. In further aspects, disclosed compositions are administered to a mammal in conjunction with an antigen to enhance the immune response of the mammal to the antigen.
    Type: Application
    Filed: March 31, 2017
    Publication date: October 5, 2017
    Inventors: Steven Dow, Michael R. Lappin, William H. Wheat, Lyndah Chow, Daniel P. Regan, Thomas J. Anchordoquy
  • Patent number: 7914714
    Abstract: The methods of the invention employ electrostatic atomization to form a compound droplet of at least two miscible fluids. The compound droplet comprises a core of a first fluid and a layer of a second fluid completely surrounding the core. The first fluid contains the agent to be encapsulated and the second fluid contains an encapsulating agent. The first and second liquids are miscible. The encapsulated droplets can contain a variety of materials including, but not limited to, polynucleotides such as DNA and RNA, proteins, bioactive agents or drugs, food, pesticides, herbicides, fragrances, antifoulants, dyes, oils, inks, cosmetics, catalysts, detergents, curing agents, flavors, fuels, metals, paints, photographic agents, biocides, pigments, plasticizers, propellants and the like and components thereof. The droplets can be encapsulated by a variety of materials, including, but not limited to, lipid bilayers and polymer shells.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: March 29, 2011
    Assignee: The Regents of the University of Colorado
    Inventors: Thomas J. Anchordoquy, Corinne Lengsfeld, Kelly Brinkley, Ryan Jones